Peter Jones
Laboratory

Epigenetic Therapies

Our laboratory focuses on the mechanisms by which epigenetic processes become misregulated in cancer and contribute to the disease phenotype. We focus on the role of DNA methylation in controlling the expression of genes during normal development and in cancer. Our work has shifted to a holistic approach in which we are interested in the interactions between processes such as DNA methylation, histone modification and nucleosomal positioning to structure the epigenome and we want to determine how mutations in the genes which modify the epigenome contribute to the cancer phenotype. We have had a longstanding interest in the mechanism of action of DNA methylation inhibitors both in the lab and in the clinic. In the clinic, we are working with several major institutions to bring epigenetic therapies to the forefront of cancer medicine.

About Epigenetics

Epigenetics may be defined as mitotically heritable changes in gene expression which are not caused by changes in the DNA sequence itself. Epigenetic processes establish the differentiated state of cells and govern how genes are used in the different cells in our bodies to allow organs and different cell types to function correctly and inherit their properties through cell division. These processes can go wrong during the formation of diseases including cancer and thus change the behavior of cells so that they don’t perform as they should. Importantly, many of these changes are potentially reversible and can be changed by treatment with appropriate drugs. Since epigenetic processes are at the root of biology they have implications in all of human development and disease.

Our Impact

We’re raising thousands to save millions.

We’re turning hope into action for the millions of people around the world affected by diseases like cancer and Parkinson’s. Find out how you can help us make a difference.

  • 141 peer-reviewed papers published in 2025, 74 of which were in high-impact journals
  • 15 VAI-SU2C Epigenetics Dream Team clinical trials launched to date
  • 10 clinical trials and related projects supported by VAI through the International Linked Clinical Trials Program

Peter A. Jones, Ph.D., D.Sc. (hon)

Distinguished Professor, Department of Epigenetics

Areas of Expertise

Epigenetics, DNA methylation, epigenetic therapies

Biography

Dr. Peter A. Jones was born in Cape Town, raised and attended college in Rhodesia (now Zimbabwe), and received his Ph.D. from the University of London. He joined the University of Southern California in 1977 and served as director of the USC Norris Comprehensive Cancer Center between 1993 and 2011. In 2014, he was appointed chief scientific officer of Van Andel Institute in Grand Rapids, Michigan, a position he held until he returned to the lab full time in 2026. Jones also served as president of VAI and its Graduate School from 2024 to 2026. Under his leadership, the Institute grew into a world leader in cancer epigenetics and was ranked no. 5 among North American nonprofit research institutes in biological sciences by the Nature Index in 2025.

His laboratory discovered the effects of 5-azacytidine on cytosine methylation and he first established the link between DNA methylation, gene expression and differentiation. He pioneered the field of epigenetics, particularly its role in cancer, and helped develop novel therapies for cancer. Dr. Jones is a past president of the American Association for Cancer Research, a Fellow of the AACR Academy, a Fellow of the American Association for the Advancement of Science, a member of the National Academy of Sciences, a member of National Academy of Medicine and a fellow of the American Academy of Arts and Sciences. He has published more than 300 scientific papers and received several honors, including the Outstanding Investigator Award from the National Cancer Institute. He and his colleague Dr. Stephen Baylin shared the Kirk A. Landon Award for Basic Cancer Research from the AACR in 2009 and the Medal of Honor from the American Cancer Society in 2011. He shared the 2022-2023 Harvey Prize in Science and Technology with Drs. Stephen Baylin and Andrew Feinberg for their groundbreaking work in cancer epigenetics.

Selected Publications

For a full list of publications, please visit Google Scholar ➔

# Equal contributions * Co-corresponding authors

Braelyn Binkowski

Braelyn Binkowski

Ph.D. Student, VAI Graduate School

Research focus to be determined.

Jennifer Brooks

Senior Administrative Assistant I, Department of Epigenetics

Xiaoying Chen, Ph.D.

Postdoctoral Fellow, Jones Laboratory

Minmin Liu, Ph.D.

Senior Research Scientist, Department of Epigenetics

Adam Olson, Ph.D.

Postdoctoral Fellow, Jones Laboratory

Rachel Shereda, B.S.

Research Technician, Department of Epigenetics

Stacey Thomas, Ph.D.

Senior Lab Manager, Department of Epigenetics

Guillermo Urrutia, M.D.

Research Scientist, Department of Epigenetics

Lab Alumni

Brittany Carpenter, Ph.D.

Postdoctoral Fellow

H. Josh Jang, Ph.D.

Postdoctoral Fellow

HyeonJin Kim

Assistant Research Technician

Ire Kim

Student Intern

Justin Kulchycki

Senior Research Technician

Hyein Lee

Assistant Research Technician

Young Sung Lee

Laboratory Aide

Seth Nelson

Assistant Research Technician

Amy Nuffesse

Senior Administrative Assistant II, Department of Epigenetics

Audrey Nguyen

Assistant Research Technician

Hitoshi Ohtani, Ph.D.

Postdoctoral Fellow

Steve Pierce, Ph.D.

Computational Biologist III

Anthony Popkie, Ph.D.

Laboratory Manager

Rochelle Tiedemann, Ph.D.

Research Scientist

Ashley Wiseman, M.S.

Research Associate

Xiaoyan Xie, Ph.D.

Research Scientist

Tinghai (Peter) Xu, Ph.D.

Research Scientist

Jueng Soo You, Ph.D.

Visiting Scientist, Department of Epigenetics

Wanding Zhou, Ph.D.

Postdoctoral Fellow